1
|
Sakthivel R, Criado-Marrero M, Barroso D, Braga IM, Bolen M, Rubinovich U, Hery GP, Grudny MM, Koren J, Prokop S, Febo M, Abisambra JF. Fixed Time-Point Analysis Reveals Repetitive Mild Traumatic Brain Injury Effects on Resting State Functional Magnetic Resonance Imaging Connectivity and Neuro-Spatial Protein Profiles. J Neurotrauma 2023; 40:2037-2049. [PMID: 37051703 PMCID: PMC10541943 DOI: 10.1089/neu.2022.0464] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/14/2023] Open
Abstract
Repetitive mild traumatic brain injuries (rmTBIs) are serious trauma events responsible for the development of numerous neurodegenerative disorders. A major challenge in developing diagnostics and treatments for the consequences of rmTBI is the fundamental knowledge gaps of the molecular mechanisms responsible for neurodegeneration. It is both critical and urgent to understand the neuropathological and functional consequences of rmTBI to develop effective therapeutic strategies. Using the Closed-Head Impact Model of Engineered Rotational Acceleration, or CHIMERA, we measured neural changes following injury, including brain volume, diffusion tensor imaging, and resting-state functional magnetic resonance imaging coupled with graph theory and functional connectivity analyses. We determined the effect of rmTBI on markers of gliosis and used NanoString-GeoMx to add a digital-spatial protein profiling analysis of neurodegenerative disease-associated proteins in gray and white matter regions. Our analyses revealed aberrant connectivity changes in the thalamus, independent of microstructural damage or neuroinflammation. We also identified distinct changes in the levels of proteins linked to various neurodegenerative processes including total and phospho-tau species and cell proliferation markers. Together, our data show that rmTBI significantly alters brain functional connectivity and causes distinct protein changes in morphologically intact brain areas.
Collapse
Affiliation(s)
- Ravi Sakthivel
- Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville, Florida, USA
- Department of Neuroscience, University of Florida, Gainesville, Florida, USA
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
| | - Marangelie Criado-Marrero
- Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville, Florida, USA
- Department of Neuroscience, University of Florida, Gainesville, Florida, USA
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
| | - Daylin Barroso
- Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville, Florida, USA
- Department of Neuroscience, University of Florida, Gainesville, Florida, USA
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
| | - Isadora M. Braga
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
| | - Mackenzie Bolen
- Department of Neuroscience, University of Florida, Gainesville, Florida, USA
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
| | - Uriel Rubinovich
- Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville, Florida, USA
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
| | - Gabriela P. Hery
- Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville, Florida, USA
- Department of Pathology, University of Florida, Gainesville, Florida, USA
| | - Matteo M. Grudny
- Department of Psychiatry, University of Florida, Gainesville, Florida, USA
| | - John Koren
- Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville, Florida, USA
- Department of Neuroscience, University of Florida, Gainesville, Florida, USA
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
| | - Stefan Prokop
- Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville, Florida, USA
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
- Department of Pathology, University of Florida, Gainesville, Florida, USA
- Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, USA
| | - Marcelo Febo
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
- Department of Psychiatry, University of Florida, Gainesville, Florida, USA
| | - Jose Francisco Abisambra
- Center for Translational Research in Neurodegenerative Disease (CTRND), University of Florida, Gainesville, Florida, USA
- Department of Neuroscience, University of Florida, Gainesville, Florida, USA
- McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
- Brain Injury Rehabilitation and Neuroresilience (BRAIN) Center, University of Florida, Gainesville, Florida, USA
| |
Collapse
|
2
|
Lessard CB, Koren J, Abisambra JFF. Tau‐RNA complexes contribute to the pathogenesis and progression in Alzheimer’s disease and related tauopathies. Alzheimers Dement 2022. [DOI: 10.1002/alz.069399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - John Koren
- University of Florida Gainesville FL USA
| | | |
Collapse
|
3
|
Cloyd RA, Koren J, Abisambra JF, Smith BN. Effects of altered tau expression on dentate granule cell excitability in mice. Exp Neurol 2021; 343:113766. [PMID: 34029610 DOI: 10.1016/j.expneurol.2021.113766] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 05/05/2021] [Accepted: 05/19/2021] [Indexed: 12/18/2022]
Abstract
Tauopathies, including Alzheimer's disease, are characterized by progressive accumulation of hyperphosphorylated and pathologic tau protein in association with onset of cognitive and behavioral impairment. Tau pathology is also associated with increased susceptibility to seizures and epilepsy, with tau-/- mice showing seizure resistance in some epilepsy models. To better understand how tau pathology is related to neuronal excitability, we performed whole-cell patch-clamp electrophysiology in dentate gyrus granule cells of tau-/- and human-tau expressing, htau mice. The htau mouse is unique from other transgenic tau models in that the endogenous murine tau gene has been and replaced with readily phosphorylated human tau. We assessed several measures of neuronal excitability, including evoked action potential frequency and excitatory synaptic responses in dentate granule cells from tau-/-, htau, and non-transgenic control mice at 1.5, 4, and 9 months of age. Compared to age matched controls, dentate granule cells from both tau-/- and htau mice had a lower peak frequency of evoked action potentials and greater paired pulse facilitation, suggesting reduced neuronal excitability. Our results suggest that neuronal excitability is more strongly influenced by the absence of functional tau than by the presence of pathologic tau. These results also suggest that tau's effect on neuronal excitability is more complex than previously understood.
Collapse
Affiliation(s)
- Ryan A Cloyd
- Department of Physiology, University of Kentucky College of Medicine, Lexington, KY 40536, USA
| | - John Koren
- Department of Neuroscience & Center for Translational Research in Neurodegenerative Diseases, University of Florida, Gainesville, FL 32610, USA
| | - Jose F Abisambra
- Department of Physiology, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Department of Neuroscience & Center for Translational Research in Neurodegenerative Diseases, University of Florida, Gainesville, FL 32610, USA
| | - Bret N Smith
- Department of Physiology, University of Kentucky College of Medicine, Lexington, KY 40536, USA; Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
| |
Collapse
|
4
|
Mishra SJ, Liu W, Beebe K, Banerjee M, Kent CN, Munthali V, Koren J, Taylor JA, Neckers LM, Holzbeierlein J, Blagg BSJ. The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition. J Med Chem 2021; 64:1545-1557. [PMID: 33428418 DOI: 10.1021/acs.jmedchem.0c01700] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials for the treatment of cancer, all of which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90 isoforms, which may lead to adverse effects. The development of Hsp90 isoform-selective inhibitors represents an alternative approach toward the treatment of cancer and may limit some of these detriments. Described herein, is a structure-based approach to develop isoform-selective inhibitors of Hsp90β, which induces the degradation of select Hsp90 clients without concomitant induction of Hsp90 levels. Together, these initial studies support the development of Hsp90β-selective inhibitors as a method for overcoming the detriments associated with pan-inhibition.
Collapse
Affiliation(s)
- Sanket J Mishra
- Department of Chemistry and Biochemistry, The University of Notre Dame, 305 McCourtney Hall, Notre Dame, Indiana 46556, United States
| | - Weiya Liu
- Department of Urologic Oncology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, United States
| | - Kristin Beebe
- Center for Cancer Research, National Cancer Institute, Building 10 - Hatfield CRC, Rockville, Maryland 20892, United States
| | - Monimoy Banerjee
- Department of Chemistry and Biochemistry, The University of Notre Dame, 305 McCourtney Hall, Notre Dame, Indiana 46556, United States
| | - Caitlin N Kent
- Department of Chemistry and Biochemistry, The University of Notre Dame, 305 McCourtney Hall, Notre Dame, Indiana 46556, United States
| | - Vitumbiko Munthali
- Department of Chemistry and Biochemistry, The University of Notre Dame, 305 McCourtney Hall, Notre Dame, Indiana 46556, United States
| | - John Koren
- Department of Chemistry and Biochemistry, The University of Notre Dame, 305 McCourtney Hall, Notre Dame, Indiana 46556, United States
| | - John A Taylor
- Department of Urologic Oncology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, United States
| | - Leonard M Neckers
- Center for Cancer Research, National Cancer Institute, Building 10 - Hatfield CRC, Rockville, Maryland 20892, United States
| | - Jeffrey Holzbeierlein
- Department of Urologic Oncology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, United States
| | - Brian S J Blagg
- Department of Chemistry and Biochemistry, The University of Notre Dame, 305 McCourtney Hall, Notre Dame, Indiana 46556, United States
| |
Collapse
|
5
|
Keegan BM, Koren J, Blagg BS. Disruptors of the Hsp90/Aha1 complex that reduce tau aggregation. Alzheimers Dement 2020. [DOI: 10.1002/alz.045193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | - John Koren
- University of Notre Dame Notre Dame IN USA
| | | | | |
Collapse
|
6
|
Sykorova A, Mocikova H, Lukasova M, Koren J, Stepankova P, Prochazka V, Belada D, Klaskova K, Gaherova L, Chroust K, Buresova L, Markova J. Outcome of elderly patients with classical Hodgkin’s lymphoma. Leuk Res 2020; 90:106311. [DOI: 10.1016/j.leukres.2020.106311] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2019] [Revised: 01/18/2020] [Accepted: 01/22/2020] [Indexed: 11/27/2022]
|
7
|
Kumar FN, Huizar F, Unger M, Soundarrajan D, Velagala V, Koren J, Zartman JJ. Neurotransmitter Receptors as Key Physiological Regulators of Epithelial Morphogenesis. Biophys J 2020. [DOI: 10.1016/j.bpj.2019.11.673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
8
|
Darling AL, Breydo L, Rivas EG, Gebru NT, Zheng D, Baker JD, Blair LJ, Dickey CA, Koren J, Uversky VN. Repeated repeat problems: Combinatorial effect of C9orf72-derived dipeptide repeat proteins. Int J Biol Macromol 2019; 127:136-145. [PMID: 30639592 DOI: 10.1016/j.ijbiomac.2019.01.035] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Revised: 12/16/2018] [Accepted: 01/08/2019] [Indexed: 12/26/2022]
Abstract
A microsatellite expansion mutation in C9orf72 is the most common genetic cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The expansion mutation leads to C9orf72 loss of function, RNA foci formation, and generation of five species of non-AUG RAN translated dipeptide repeat proteins (DPRs), such as poly(GA), poly(GP), poly(GR), poly(PA), and poly(PR). Although one cell can contain more than type of DPRs, information about interplay between different DPR species is limited. Here we show that the combined expression of distinct C9orf72-derived dipeptide repeat species produces cellular outcomes and structural differences that are unique compared to the expression of a single DPR species, suggesting the complex biological interactions that occur when multiple DPR variants are simultaneously expressed. Our data highlights the need for further analysis of how combined expression of different DPRs affects the disease state.
Collapse
Affiliation(s)
- April L Darling
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA.
| | - Leonid Breydo
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA
| | - Emma G Rivas
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA
| | - Niad T Gebru
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA
| | - Dali Zheng
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA
| | - Jeremy D Baker
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA
| | - Laura J Blair
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA
| | - Chad A Dickey
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA
| | - John Koren
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA.
| | - Vladimir N Uversky
- Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL 33612, USA; Institute for Biological Instrumentation of the Russian Academy of Sciences, Pushchino, Moscow Region 142290, Russia.
| |
Collapse
|
9
|
Koren J, Hubenakova Z, Drahovska H, Ozaee E, Markuskova B, Lichvarikova A. Emergence of extended-spectrum β-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae (CPE) and their antimicrobial resistance. BRATISL MED J 2019; 120:935-940. [DOI: 10.4149/bll_2019_157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
10
|
Kishinevsky S, Wang T, Rodina A, Chung SY, Xu C, Philip J, Taldone T, Joshi S, Alpaugh ML, Bolaender A, Gutbier S, Sandhu D, Fattahi F, Zimmer B, Shah SK, Chang E, Inda C, Koren J, Saurat NG, Leist M, Gross SS, Seshan VE, Klein C, Tomishima MJ, Erdjument-Bromage H, Neubert TA, Henrickson RC, Chiosis G, Studer L. HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nat Commun 2018; 9:4345. [PMID: 30341316 PMCID: PMC6195591 DOI: 10.1038/s41467-018-06486-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 08/29/2018] [Indexed: 12/21/2022] Open
Abstract
Environmental and genetic risk factors contribute to Parkinson’s Disease (PD) pathogenesis and the associated midbrain dopamine (mDA) neuron loss. Here, we identify early PD pathogenic events by developing methodology that utilizes recent innovations in human pluripotent stem cells (hPSC) and chemical sensors of HSP90-incorporating chaperome networks. We show that events triggered by PD-related genetic or toxic stimuli alter the neuronal proteome, thereby altering the stress-specific chaperome networks, which produce changes detected by chemical sensors. Through this method we identify STAT3 and NF-κB signaling activation as examples of genetic stress, and phospho-tyrosine hydroxylase (TH) activation as an example of toxic stress-induced pathways in PD neurons. Importantly, pharmacological inhibition of the stress chaperome network reversed abnormal phospho-STAT3 signaling and phospho-TH-related dopamine levels and rescued PD neuron viability. The use of chemical sensors of chaperome networks on hPSC-derived lineages may present a general strategy to identify molecular events associated with neurodegenerative diseases. The early molecular events that ultimately lead to neuronal cell death in pathologies such as Parkinson’s disease are poorly understood. Here the authors use pluripotent stem-cell-derived human midbrain neurons and chemical biology tools to gain molecular level insight into the events induced by toxic and genetic stresses that mimic those occurring during neurodegeneration.
Collapse
Affiliation(s)
- Sarah Kishinevsky
- The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Neuroscience Graduate Program of Weill Cornell Graduate School of Biomedical Sciences, Weill Cornell Medical College, 1300 York Avenue, Box 65, New York, NY, 10065, USA
| | - Tai Wang
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Anna Rodina
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Sun Young Chung
- The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA
| | - Chao Xu
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - John Philip
- Proteomics Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Tony Taldone
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Suhasini Joshi
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Mary L Alpaugh
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Department of Molecular and Cellular Biosciences, Rowan University, 1275 York Avenue, Glassboro, NJ, 08028, USA
| | - Alexander Bolaender
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Simon Gutbier
- Doerenkamp-Zbinden Chair for In Vitro Toxicology and Biomedicine, University of Konstanz, Konstanz, 78464, Germany
| | - Davinder Sandhu
- Department of Pharmacology, Weill Cornell College of Medicine, 1300 York Avenue, New York, NY, 10065, USA
| | - Faranak Fattahi
- The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA
| | - Bastian Zimmer
- The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA
| | - Smit K Shah
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Elizabeth Chang
- Proteomics Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Carmen Inda
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Hostos Community College, City University of New York, Bronx, NY, 10453, USA
| | - John Koren
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.,Department of Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA
| | - Nathalie G Saurat
- The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA
| | - Marcel Leist
- Doerenkamp-Zbinden Chair for In Vitro Toxicology and Biomedicine, University of Konstanz, Konstanz, 78464, Germany
| | - Steven S Gross
- Department of Pharmacology, Weill Cornell College of Medicine, 1300 York Avenue, New York, NY, 10065, USA
| | - Venkatraman E Seshan
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10017, USA
| | - Christine Klein
- Institute of Neurogenetics, University of Lübeck, Lübeck, 23538, Germany
| | - Mark J Tomishima
- The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,SKI Stem Cell Research Facility, 1275 York Avenue, Sloan Kettering Institute, New York, NY, 10065, USA
| | - Hediye Erdjument-Bromage
- Department of Cell Biology, NYU School of Medicine, New York, NY, 10016, USA.,Kimmel Center for Biology and Medicine at the Skirball Institute, NYU School of Medicine, New York, NY, 10016, USA
| | - Thomas A Neubert
- Department of Cell Biology, NYU School of Medicine, New York, NY, 10016, USA.,Kimmel Center for Biology and Medicine at the Skirball Institute, NYU School of Medicine, New York, NY, 10016, USA
| | - Ronald C Henrickson
- Proteomics Core Facility, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
| | - Gabriela Chiosis
- Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. .,Department of Medicine, Memorial Hospital, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
| | - Lorenz Studer
- The Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA.,Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 256, New York, NY, 10065, USA
| |
Collapse
|
11
|
Sabbagh JJ, Cordova RA, Zheng D, Criado-Marrero M, Lemus A, Li P, Baker JD, Nordhues BA, Darling AL, Martinez-Licha C, Rutz DA, Patel S, Buchner J, Leahy JW, Koren J, Dickey CA, Blair LJ. Targeting the FKBP51/GR/Hsp90 Complex to Identify Functionally Relevant Treatments for Depression and PTSD. ACS Chem Biol 2018; 13:2288-2299. [PMID: 29893552 DOI: 10.1021/acschembio.8b00454] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Genetic and epigenetic alterations in FK506-binding protein 5 ( FKBP5) have been associated with increased risk for psychiatric disorders, including post-traumatic stress disorder (PTSD). Some of these common variants can increase the expression of FKBP5, the gene that encodes FKBP51. Excess FKBP51 promotes hypothalamic-pituitary-adrenal (HPA) axis dysregulation through altered glucocorticoid receptor (GR) signaling. Thus, we hypothesized that GR activity could be restored by perturbing FKBP51. Here, we screened 1280 pharmacologically active compounds and identified three compounds that rescued FKBP51-mediated suppression of GR activity without directly activating GR. One of the three compounds, benztropine mesylate, disrupted the association of FKBP51 with the GR/Hsp90 complex in vitro. Moreover, we show that removal of FKBP51 from this complex by benztropine restored GR localization in ex vivo brain slices and primary neurons from mice. In conclusion, we have identified a novel disruptor of the FKBP51/GR/Hsp90 complex. Targeting this complex may be a viable approach to developing treatments for disorders related to aberrant FKBP51 expression.
Collapse
Affiliation(s)
- Jonathan J. Sabbagh
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Ricardo A. Cordova
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Dali Zheng
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Marangelie Criado-Marrero
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Andrea Lemus
- Department of Chemistry, University of South Florida, Tampa, Florida, United States of America
| | - Pengfei Li
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Jeremy D. Baker
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Bryce A. Nordhues
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - April L. Darling
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Carlos Martinez-Licha
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Daniel A. Rutz
- Department Chemie, Technische Universität München, 85748 Munich, Germany
| | - Shreya Patel
- Department of Chemistry, University of South Florida, Tampa, Florida, United States of America
| | - Johannes Buchner
- Department Chemie, Technische Universität München, 85748 Munich, Germany
| | - James W. Leahy
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- Department of Chemistry, University of South Florida, Tampa, Florida, United States of America
- Center for Drug Discovery and Innovation, University of South Florida, Tampa, Florida, United States of America
| | - John Koren
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Chad A. Dickey
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| | - Laura J. Blair
- Department of Molecular Medicine, University of South Florida, Tampa, Florida, United States of America
- USF Health Byrd Institute, University of South Florida, Tampa, Florida, United States of America
| |
Collapse
|
12
|
Criado-Marrero M, Rein T, Binder EB, Porter JT, Koren J, Blair LJ. Hsp90 and FKBP51: complex regulators of psychiatric diseases. Philos Trans R Soc Lond B Biol Sci 2018; 373:rstb.2016.0532. [PMID: 29203717 DOI: 10.1098/rstb.2016.0532] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2017] [Accepted: 09/11/2017] [Indexed: 01/30/2023] Open
Abstract
Mood disorders affect nearly a quarter of the world's population. Therefore, understanding the molecular mechanisms underlying these conditions is of great importance. FK-506 binding protein 5 (FKBP5) encodes the FKBP51 protein, a heat shock protein 90 kDa (Hsp90) co-chaperone, and is a risk factor for several affective disorders. FKBP51, in coordination with Hsp90, regulates glucocorticoid receptor (GR) activity via a short negative feedback loop. This signalling pathway rapidly restores homeostasis in the hypothalamic-pituitary-adrenal (HPA) axis following stress. Expression of FKBP5 increases with age through reduced DNA methylation. High levels of FKBP51 are linked to GR resistance and reduced stress coping behaviour. Moreover, common allelic variants in the FKBP5 gene are associated with increased risk of developing affective disorders like anxiety, depression and post-traumatic stress disorder (PTSD). This review highlights the current understanding of the Hsp90 co-chaperone, FKBP5, in disease from both human and animal studies. In addition, FKBP5 genetic implications in the clinic involving life stress exposure, gender differences and treatment outcomes are discussed.This article is part of the theme issue 'Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective'.
Collapse
Affiliation(s)
- Marangelie Criado-Marrero
- Department of Molecular Medicine, Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL 33613, USA
| | - Theo Rein
- Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany
| | - Elisabeth B Binder
- Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.,Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30307, USA
| | - James T Porter
- Department of Basic Sciences, Ponce Health Sciences University-School of Medicine/Ponce Research Institute, Ponce, Puerto Rico 00732, USA
| | - John Koren
- Department of Molecular Medicine, Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL 33613, USA
| | - Laura J Blair
- Department of Molecular Medicine, Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL 33613, USA
| |
Collapse
|
13
|
Huard DJE, Crowley VM, Du Y, Cordova RA, Sun Z, Tomlin MO, Dickey CA, Koren J, Blair L, Fu H, Blagg BSJ, Lieberman RL. Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma. ACS Chem Biol 2018; 13:933-941. [PMID: 29402077 PMCID: PMC6195314 DOI: 10.1021/acschembio.7b01083] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Gain-of-function mutations within the olfactomedin (OLF) domain of myocilin result in its toxic intracellular accumulation and hasten the onset of open-angle glaucoma. The absence of myocilin does not cause disease; therefore, strategies aimed at eliminating myocilin could lead to a successful glaucoma treatment. The endoplasmic reticulum Hsp90 paralog Grp94 accelerates OLF aggregation. Knockdown or pharmacological inhibition of Grp94 in cells facilitates clearance of mutant myocilin via a non-proteasomal pathway. Here, we expanded our support for targeting Grp94 over cytosolic paralogs Hsp90α and Hsp90β. We then developed a high-throughput screening assay to identify new chemical matter capable of disrupting the Grp94/OLF interaction. When applied to a blind, focused library of 17 Hsp90 inhibitors, our miniaturized single-read in vitro thioflavin T -based kinetics aggregation assay exclusively identified compounds that target the chaperone N-terminal nucleotide binding site. In follow up studies, one compound (2) decreased the extent of co-aggregation of Grp94 with OLF in a dose-dependent manner in vitro, and enabled clearance of the aggregation-prone full-length myocilin variant I477N in cells without inducing the heat shock response or causing cytotoxicity. Comparison of the co-crystal structure of compound 2 and another non-selective hit in complex with the N-terminal domain of Grp94 reveals a docking mode tailored to Grp94 and explains its selectivity. A new lead compound has been identified, supporting a targeted chemical biology assay approach to develop a protein degradation-based therapy for myocilin-associated glaucoma by selectively inhibiting Grp94.
Collapse
Affiliation(s)
| | - Vincent M. Crowley
- Emory Chemical Biology Discovery Center, Department of Pharmacology, Emory University
| | - Yuhong Du
- Department of Medicinal Chemistry, The University of Kansas
| | - Ricardo A. Cordova
- Byrd Alzheimer Institute, Department of Molecular Medicine, University of South Florida
| | - Zheying Sun
- Byrd Alzheimer Institute, Department of Molecular Medicine, University of South Florida
| | - Moya O. Tomlin
- School of Chemistry & Biochemistry, Georgia Institute of Technology
| | - Chad A. Dickey
- Byrd Alzheimer Institute, Department of Molecular Medicine, University of South Florida
| | - John Koren
- Byrd Alzheimer Institute, Department of Molecular Medicine, University of South Florida
| | - Laura Blair
- Byrd Alzheimer Institute, Department of Molecular Medicine, University of South Florida
| | - Haian Fu
- Department of Medicinal Chemistry, The University of Kansas
| | - Brian S. J. Blagg
- Emory Chemical Biology Discovery Center, Department of Pharmacology, Emory University
- Department of Chemistry and Biochemistry, The University of Notre Dame
| | | |
Collapse
|
14
|
Darling A, Braydo L, Blair L, Koren J, Uversky V. Repeat Problems: Combinatorial Effect of
C9orf72
‐Derived Dipeptide Repeat Proteins. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.526.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- April Darling
- Molecular MedicineUniversity of South FloridaTampaFL
| | - Leonid Braydo
- Molecular MedicineUniversity of South FloridaTampaFL
- James A. Haley Veteran's HospitalTampaFL
| | - Laura Blair
- Molecular MedicineUniversity of South FloridaTampaFL
- James A. Haley Veteran's HospitalTampaFL
| | - John Koren
- Molecular MedicineUniversity of South FloridaTampaFL
- James A. Haley Veteran's HospitalTampaFL
| | - Vladimir Uversky
- Molecular MedicineUniversity of South FloridaTampaFL
- Institute for Biological Instrumentation of the Russian Academy of SciencesPushchinoRussian Federation
| |
Collapse
|
15
|
Abstract
The ATP-dependent 90 kDa heat shock protein, Hsp90, is a major regulator of protein triage, from assisting in nascent protein folding to refolding or degrading aberrant proteins. Tau, a microtubule associated protein, aberrantly accumulates in Alzheimer's disease (AD) and other neurodegenerative diseases, deemed tauopathies. Hsp90 binds to and regulates tau fate in coordination with a diverse group of co-chaperones. Imbalances in chaperone levels and activity, as found in the aging brain, can contribute to disease onset and progression. For example, the levels of the Hsp90 co-chaperone, FK506-binding protein 51 kDa (FKBP51), progressively increase with age. In vitro and in vivo tau models demonstrated that FKBP51 synergizes with Hsp90 to increase neurotoxic tau oligomer production. Inversely, protein phosphatase 5 (PP5), which dephosphorylates tau to restore microtubule-binding function, is repressed with aging and activity is further repressed in AD. Similarly, levels of cyclophilin 40 (CyP40) are reduced in the aged brain and further repressed in AD. Interestingly, CyP40 was shown to breakup tau aggregates in vitro and prevent tau-induced neurotoxicity in vivo. Moreover, the only known stimulator of Hsp90 ATPase activity, Aha1, increases tau aggregation and toxicity. While the levels of Aha1 are not significantly altered with aging, increased levels have been found in AD brains. Overall, these changes in the Hsp90 heterocomplex could drive tau deposition and neurotoxicity. While the relationship of tau and Hsp90 in coordination with these co-chaperones is still under investigation, it is clear that imbalances in these proteins with aging can contribute to disease onset and progression. This review highlights the current understanding of how the Hsp90 family of molecular chaperones regulates tau or other misfolded proteins in neurodegenerative diseases with a particular emphasis on the impact of aging.
Collapse
Affiliation(s)
- Lindsey B Shelton
- Department of Molecular Medicine and USF Health Byrd Institute, University of South Florida, Tampa, FL, United States
| | - John Koren
- Department of Molecular Medicine and USF Health Byrd Institute, University of South Florida, Tampa, FL, United States
| | - Laura J Blair
- Department of Molecular Medicine and USF Health Byrd Institute, University of South Florida, Tampa, FL, United States
| |
Collapse
|
16
|
Stothert AR, Suntharalingam A, Tang X, Crowley VM, Mishra SJ, Webster JM, Nordhues BA, Huard DJE, Passaglia CL, Lieberman RL, Blagg BSJ, Blair LJ, Koren J, Dickey CA. Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma. Sci Rep 2017; 7:17951. [PMID: 29263415 PMCID: PMC5738387 DOI: 10.1038/s41598-017-18344-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Accepted: 12/11/2017] [Indexed: 12/26/2022] Open
Abstract
The heat shock protein 90 (Hsp90) family of molecular chaperones regulates protein homeostasis, folding, and degradation. The ER-resident Hsp90 isoform, glucose-regulated protein 94 (Grp94), promotes the aggregation of mutant forms of myocilin, a protein associated with primary open-angle glaucoma. While inhibition of Grp94 promotes the degradation of mutant myocilin in vitro, to date no Grp94-selective inhibitors have been investigated in vivo. Here, a Grp94-selective inhibitor facilitated mutant myocilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle glaucoma. Ocular toxicities previously associated with pan-Hsp90 inhibitors were not evident with our Grp94-selective inhibitor, 4-Br-BnIm. Our study suggests that selective inhibition of a distinct Hsp90 family member holds translational promise for ocular and other diseases associated with cell stress and protein misfolding.
Collapse
Affiliation(s)
- Andrew R Stothert
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, 33613, USA
| | - Amirthaa Suntharalingam
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, 33613, USA
| | - Xiaolan Tang
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, 33613, USA.,Department of Chemical & Biomedical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33613, USA
| | - Vincent M Crowley
- Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS, 66045, USA
| | - Sanket J Mishra
- Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS, 66045, USA
| | - Jack M Webster
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, 33613, USA
| | - Bryce A Nordhues
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, 33613, USA
| | - Dustin J E Huard
- School of Chemistry & Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332, USA
| | - Christopher L Passaglia
- Department of Chemical & Biomedical Engineering, College of Engineering, University of South Florida, Tampa, FL, 33613, USA
| | - Raquel L Lieberman
- School of Chemistry & Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332, USA
| | - Brian S J Blagg
- Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS, 66045, USA
| | - Laura J Blair
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, 33613, USA.
| | - John Koren
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, 33613, USA.
| | - Chad A Dickey
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL, 33613, USA
| |
Collapse
|
17
|
Baker JD, Breydo L, Dickey CA, Blair LJ, Koren J. [P4–103]: PROLINE ISOMERIZATION CONTROLS TOXIC AMYLOID FORMATION. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.1969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Trneny M, Campr V, Pytlik R, Klener P, Stritesky J, Jaksa R, Boudova L, Benesova K, Koren J, Trnkova M, Blahovcova P, Klanova M. DOUBLE-EXPRESSOR LYMPHOMAS DO NOT HAVE INFERIOR OUTCOME AFTER AUTOLOGOUS STEM-CELL TRANSPLANT IN THE FIRST LINE TREATMENT. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Trneny
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - V. Campr
- Dept Pathology; University Hospital Motol; Praha Czech Republic
| | - R. Pytlik
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - P. Klener
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - J. Stritesky
- Department of Pathology; Charles University General Hospital; Prague 2 Czech Republic
| | - R. Jaksa
- Department of Pathology; Charles University General Hospital; Prague 2 Czech Republic
| | - L. Boudova
- Department of Pathology; University Hospital Plzen; Plzen Czech Republic
| | - K. Benesova
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - J. Koren
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - M. Trnkova
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - P. Blahovcova
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| | - M. Klanova
- 1st Dept Med; Charles General University Hospital; Praha Czech Republic
| |
Collapse
|
19
|
Baker JD, Shelton LB, Zheng D, Favretto F, Nordhues BA, Darling A, Sullivan LE, Sun Z, Solanki PK, Martin MD, Suntharalingam A, Sabbagh JJ, Becker S, Mandelkow E, Uversky VN, Zweckstetter M, Dickey CA, Koren J, Blair LJ. Human cyclophilin 40 unravels neurotoxic amyloids. PLoS Biol 2017; 15:e2001336. [PMID: 28654636 PMCID: PMC5486962 DOI: 10.1371/journal.pbio.2001336] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 05/23/2017] [Indexed: 01/13/2023] Open
Abstract
The accumulation of amyloidogenic proteins is a pathological hallmark of neurodegenerative disorders. The aberrant accumulation of the microtubule associating protein tau (MAPT, tau) into toxic oligomers and amyloid deposits is a primary pathology in tauopathies, the most common of which is Alzheimer's disease (AD). Intrinsically disordered proteins, like tau, are enriched with proline residues that regulate both secondary structure and aggregation propensity. The orientation of proline residues is regulated by cis/trans peptidyl-prolyl isomerases (PPIases). Here we show that cyclophilin 40 (CyP40), a PPIase, dissolves tau amyloids in vitro. Additionally, CyP40 ameliorated silver-positive and oligomeric tau species in a mouse model of tau accumulation, preserving neuronal health and cognition. Nuclear magnetic resonance (NMR) revealed that CyP40 interacts with tau at sites rich in proline residues. CyP40 was also able to interact with and disaggregate other aggregating proteins that contain prolines. Moreover, CyP40 lacking PPIase activity prevented its capacity for disaggregation in vitro. Finally, we describe a unique structural property of CyP40 that may permit disaggregation to occur in an energy-independent manner. This study identifies a novel human protein disaggregase and, for the first time, demonstrates its capacity to dissolve intracellular amyloids.
Collapse
Affiliation(s)
- Jeremy D. Baker
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| | - Lindsey B. Shelton
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| | - Dali Zheng
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
| | - Filippo Favretto
- German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany
| | - Bryce A. Nordhues
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| | - April Darling
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| | - Leia E. Sullivan
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
| | - Zheying Sun
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
| | - Parth K. Solanki
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
| | - Mackenzie D. Martin
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| | - Amirthaa Suntharalingam
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
| | - Jonathan J. Sabbagh
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| | - Stefan Becker
- Department for NMR-based Structural Biology, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
| | - Eckhard Mandelkow
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- CAESAR Research Center, Bonn, Germany
- MPI for Metabolism Research, Hamburg, Germany
| | - Vladimir N. Uversky
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
| | - Markus Zweckstetter
- German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany
- Department for NMR-based Structural Biology, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
- Department of Neurology, University Medical Center Göttingen, Göttingen, Germany
| | - Chad A. Dickey
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| | - John Koren
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| | - Laura J. Blair
- Department of Molecular Medicine and Byrd Alzheimer’s Institute, University of South Florida, Tampa, Florida, United States of America
- James A. Haley Veteran's Hospital, Tampa, Florida, United States of America
| |
Collapse
|
20
|
Herta J, Koren J, Fürbass F, Hartmann M, Gruber A, Baumgartner C. Reduced electrode arrays for the automated detection of rhythmic and periodic patterns in the intensive care unit: Frequently tried, frequently failed? Clin Neurophysiol 2017; 128:1524-1531. [PMID: 28501415 DOI: 10.1016/j.clinph.2017.04.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Revised: 04/02/2017] [Accepted: 04/18/2017] [Indexed: 10/19/2022]
Abstract
OBJECTIVE To investigate the effect of systematic electrode reduction from a common 10-20 EEG system on pattern detection sensitivity (SEN). METHODS Two reviewers rated 17130 one-minute segments of 83 prospectively recorded cEEGs according to the ACNS standardized critical care EEG terminology (CCET), including burst suppression patterns (BS) and unequivocal electrographic seizures. Consensus annotations between reviewers were used as a gold standard to determine pattern detection SEN and specificity (SPE) of a computational algorithm (baseline, 19 electrodes). Electrodes were than reduced one by one in four different variations. SENs and SPEs were calculated to determine the most beneficial assembly with respect to the number and location of electrodes. RESULTS High automated baseline SENs (84.99-93.39%) and SPEs (90.05-95.6%) were achieved for all patterns. Best overall results in detecting BS and CCET patterns were found using the "hairline+vertex" montage. While the "forehead+behind ear" montage showed an advantage in detecting ictal patterns, reaching a 15% drop of SEN with 10 electrodes, all montages could detect BS sufficiently if at least nine electrodes were available. CONCLUSION For the first time an automated approach was used to systematically evaluate the effect of electrode reduction on pattern detection SEN in cEEG. SIGNIFICANCE Prediction of the expected detection SEN of specific EEG patterns with reduced EEG montages in ICU patients.
Collapse
Affiliation(s)
- J Herta
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
| | - J Koren
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria
| | - F Fürbass
- AIT Austrian Institute of Technology GmbH, Digital Safety & Security Department, Vienna, Austria
| | - M Hartmann
- AIT Austrian Institute of Technology GmbH, Digital Safety & Security Department, Vienna, Austria
| | - A Gruber
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | - C Baumgartner
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria; Department of Epileptology and Clinical Neurophysiology, Sigmund Freud University, Vienna, Austria
| |
Collapse
|
21
|
Herta J, Koren J, Fürbass F, Zöchmeister A, Hartmann M, Hosmann A, Baumgartner C, Gruber A. Applicability of NeuroTrend as a bedside monitor in the neuro ICU. Clin Neurophysiol 2017; 128:1000-1007. [PMID: 28458027 DOI: 10.1016/j.clinph.2017.04.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 03/21/2017] [Accepted: 04/02/2017] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To assess whether ICU caregivers can correctly read and interpret continuous EEG (cEEG) data displayed with the computer algorithm NeuroTrend (NT) with the main attention on seizure detection and determination of sedation depth. METHODS 120 screenshots of NT (480h of cEEG) were rated by 18 briefly trained nurses and biomedical analysts. Multirater agreements (MRA) as well as interrater agreements (IRA) compared to an expert opinion (EXO) were calculated for items such as pattern type, pattern location, interruption of recording, seizure suspicion, consistency of frequency, seizure tendency and level of sedation. RESULTS MRA as well as IRA were almost perfect (80-100%) for interruption of recording, spike-and-waves, rhythmic delta activity and burst suppression. A substantial agreement (60-80%) was found for electrographic seizure patterns, periodic discharges and seizure suspicion. Except for pattern localization (70.83-92.26%), items requiring a precondition and especially those who needed interpretation like consistency of frequency (47.47-79.15%) or level of sedation (41.10%) showed lower agreements. CONCLUSIONS The present study demonstrates that NT might be a useful bedside monitor in cases of subclinical seizures. Determination of correct sedation depth by ICU caregivers requires a more detailed training. SIGNIFICANCE Computer algorithms may reduce the workload of cEEG analysis in ICU patients.
Collapse
Affiliation(s)
- J Herta
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
| | - J Koren
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria
| | - F Fürbass
- AIT Austrian Institute of Technology GmbH, Digital Safety & Security Department, Vienna, Austria
| | - A Zöchmeister
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | - M Hartmann
- AIT Austrian Institute of Technology GmbH, Digital Safety & Security Department, Vienna, Austria
| | - A Hosmann
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | - C Baumgartner
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria; Department of Epileptology and Clinical Neurophysiology, Sigmund Freud University, Vienna, Austria
| | - A Gruber
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
22
|
Inda C, Bolaender A, Wang T, Gandu SR, Koren J. Stressing Out Hsp90 in Neurotoxic Proteinopathies. Curr Top Med Chem 2017; 16:2829-38. [PMID: 27072699 DOI: 10.2174/1568026616666160413141350] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Revised: 01/05/2016] [Accepted: 01/17/2016] [Indexed: 12/12/2022]
Abstract
A toxic accumulation of proteins is the hallmark pathology of several neurodegenerative disorders. Protein accumulation is regularly prevented by the network of molecular chaperone proteins, including and especially Hsp90. For reasons not yet elucidated, Hsp90 and the molecular chaperones interact with, but do not degrade, these toxic proteins resulting in the pathogenic accumulation of proteins such as tau, in Alzheimer's Disease, and α-synuclein, in Parkinson's Disease. In this review, we describe the associations between Hsp90 and the pathogenic and driver proteins of several neurodegenerative disorders. We additionally describe how the inhibition of Hsp90 promotes the degradation of both mutant and pathogenic protein species in models of neurodegenerative diseases. We also examine the current state of Hsp90 inhibitors capable of crossing the blood-brain barrier; compounds which may be capable of slowing, preventing, and possible reversing neurodegenerative diseases.
Collapse
Affiliation(s)
| | | | | | | | - John Koren
- Program in Chemical Biology, Memorial Sloan-Kettering Cancer Center, New York, USA.
| |
Collapse
|
23
|
Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J, Chiosis G, Sabatino D. RNAi Screening of the Glucose-Regulated Chaperones in Cancer with Self-Assembled siRNA Nanostructures. Nano Lett 2016; 16:6099-6108. [PMID: 27669096 PMCID: PMC5378679 DOI: 10.1021/acs.nanolett.6b02274] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
The emerging field of RNA nanotechnology has been used to design well-programmed, self-assembled nanostructures for applications in chemistry, biology, and medicine. At the forefront of its utility in cancer is the unrestricted ability to self-assemble multiple siRNAs within a single nanostructure formulation for the RNAi screening of a wide range of oncogenes while potentiating the gene therapy of malignant tumors. In our RNAi nanotechnology approach, V- and Y-shape RNA templates were designed and constructed for the self-assembly of discrete, higher-ordered siRNA nanostructures targeting the oncogenic glucose regulated chaperones. The GRP78-targeting siRNAs self-assembled into genetically encoded spheres, triangles, squares, pentagons and hexagons of discrete sizes and shapes according to TEM imaging. Furthermore, gel electrophoresis, thermal denaturation, and CD spectroscopy validated the prerequisite siRNA hybrids for their RNAi application. In a 24 sample siRNA screen conducted within the AN3CA endometrial cancer cells known to overexpress oncogenic GRP78 activity, the self-assembled siRNAs targeting multiple sites of GRP78 expression demonstrated more potent and long-lasting anticancer activity relative to their linear controls. Extending the scope of our RNAi screening approach, the self-assembled siRNA hybrids (5 nM) targeting of GRP-75, 78, and 94 resulted in significant (50-95%) knockdown of the glucose regulated chaperones, which led to synergistic effects in tumor cell cycle arrest (50-80%) and death (50-60%) within endometrial (AN3CA), cervical (HeLa), and breast (MDA-MB-231) cancer cell lines. Interestingly, a nontumorigenic lung (MRC5) cell line displaying normal glucose regulated chaperone levels was found to tolerate siRNA treatment and demonstrated less toxicity (5-20%) relative to the cancer cells that were found to be addicted to glucose regulated chaperones. These remarkable self-assembled siRNA nanostructures may thus encompass a new class of potent siRNAs that may be useful in screening important oncogene targets while improving siRNA therapeutic efficacy and specificity in cancer.
Collapse
Affiliation(s)
- Mayurbhai R. Patel
- Program in Chemical Biology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States
| | - Stephen D. Kozuch
- Department of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States
| | - Christopher N. Cultrara
- Department of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States
| | - Reeta Yadav
- Department of Chemistry and Biochemistry, Queens College, City University of New York, 65-30 Kissena Blvd., Flushing, New York 11367, United States
- Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City University of New York, New York City, New York 10016, United States
| | - Suiying Huang
- Department of Chemistry and Biochemistry, Queens College, City University of New York, 65-30 Kissena Blvd., Flushing, New York 11367, United States
- Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City University of New York, New York City, New York 10016, United States
| | - Uri Samuni
- Department of Chemistry and Biochemistry, Queens College, City University of New York, 65-30 Kissena Blvd., Flushing, New York 11367, United States
- Ph.D. Programs in Chemistry and Biochemistry, The Graduate Center of the City University of New York, New York City, New York 10016, United States
| | - John Koren
- Program in Chemical Biology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Gabriela Chiosis
- Program in Chemical Biology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - David Sabatino
- Department of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States
- Corresponding Author.
| |
Collapse
|
24
|
Rodina A, Wang T, Yan P, Gomes ED, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature 2016; 538:397-401. [PMID: 27706135 DOI: 10.1038/nature19807] [Citation(s) in RCA: 182] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2016] [Accepted: 09/02/2016] [Indexed: 01/01/2023]
Abstract
Transient, multi-protein complexes are important facilitators of cellular functions. This includes the chaperome, an abundant protein family comprising chaperones, co-chaperones, adaptors, and folding enzymes-dynamic complexes of which regulate cellular homeostasis together with the protein degradation machinery. Numerous studies have addressed the role of chaperome members in isolation, yet little is known about their relationships regarding how they interact and function together in malignancy. As function is probably highly dependent on endogenous conditions found in native tumours, chaperomes have resisted investigation, mainly due to the limitations of methods needed to disrupt or engineer the cellular environment to facilitate analysis. Such limitations have led to a bottleneck in our understanding of chaperome-related disease biology and in the development of chaperome-targeted cancer treatment. Here we examined the chaperome complexes in a large set of tumour specimens. The methods used maintained the endogenous native state of tumours and we exploited this to investigate the molecular characteristics and composition of the chaperome in cancer, the molecular factors that drive chaperome networks to crosstalk in tumours, the distinguishing factors of the chaperome in tumours sensitive to pharmacologic inhibition, and the characteristics of tumours that may benefit from chaperome therapy. We find that under conditions of stress, such as malignant transformation fuelled by MYC, the chaperome becomes biochemically 'rewired' to form a network of stable, survival-facilitating, high-molecular-weight complexes. The chaperones heat shock protein 90 (HSP90) and heat shock cognate protein 70 (HSC70) are nucleating sites for these physically and functionally integrated complexes. The results indicate that these tightly integrated chaperome units, here termed the epichaperome, can function as a network to enhance cellular survival, irrespective of tissue of origin or genetic background. The epichaperome, present in over half of all cancers tested, has implications for diagnostics and also provides potential vulnerability as a target for drug intervention.
Collapse
Affiliation(s)
- Anna Rodina
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Tai Wang
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Pengrong Yan
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Erica DaGama Gomes
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Mark P S Dunphy
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | | | - John Koren
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - John F Gerecitano
- Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Tony Taldone
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Hongliang Zong
- Haematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
| | - Eloisi Caldas-Lopes
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Mary Alpaugh
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Adriana Corben
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Matthew Riolo
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Brad Beattie
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Christina Pressl
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Radu I Peter
- Department of Mathematics, Technical University of Cluj-Napoca, Cluj-Napoca 400114, Romania
| | - Chao Xu
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Robert Trondl
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Hardik J Patel
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Fumiko Shimizu
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Alexander Bolaender
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Chenghua Yang
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Palak Panchal
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Mohammad F Farooq
- Molecular, Cellular &Biomedical Sciences, University of New Hampshire, Durham, New Hampshire 03824, USA
| | - Sarah Kishinevsky
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA
| | - Shanu Modi
- Breast Cancer Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Oscar Lin
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Feixia Chu
- Molecular, Cellular &Biomedical Sciences, University of New Hampshire, Durham, New Hampshire 03824, USA
| | - Sujata Patil
- Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Hediye Erdjument-Bromage
- Microchemistry and Proteomics Core, Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Pat Zanzonico
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Clifford Hudis
- Breast Cancer Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Lorenz Studer
- Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Gail J Roboz
- Haematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
| | - Ethel Cesarman
- Haematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
| | - Leandro Cerchietti
- Haematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
| | - Ross Levine
- Human Oncology and Pathogenesis Program, Sloan Kettering Institute, New York, New York 10065, USA
| | - Ari Melnick
- Haematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
| | - Steven M Larson
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Monica L Guzman
- Haematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA
| | - Gabriela Chiosis
- Program in Chemical Biology, Sloan Kettering Institute, New York, New York 10065, USA.,Breast Cancer Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| |
Collapse
|
25
|
Fürbass F, Herta J, Koren J, Skupch A, Hartmann M, Kluge T, Gruber A, Baumgartner C. ID 145 – NeuroTrend: Prospective validation of rhythmic and periodic pattern detection method for Scalp. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Rodina AA, Taldone T, Kang Y, Patel P, Koren J, Yan P, DaGama Gomes E, Yang C, Patel M, Shrestha L, Ochiana S, Maharaj R, Gozman A, Cox M, Erdjument-Bromage H, Hendrickson R, Cerchietti L, Melnick A, Guzman M, Chiosis G. Abstract 1733: Development of chemical tools to study the endogenous Hsp70 interactome in malignant cells. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-1733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Heat shock protein 70 family members play an important role in cancer. They are up-regulated in wide variety of tumors and the increased Hsp70 protein expression correlates with metastases, resistance to treatment and poor prognosis. Multiple mechanisms explain cancer cells dependence on Hsp70, such as inhibition of apoptosis by Hsp70, induction of autophagy and control of stability of onco-proteins. These Hsp70 activities are mediated in cancer by its ability to chaperone and interact with a large number of proteins in a cell-specific, context dependent manner.
Hypothesis: Reagents that enable the capture of tumor-specific Hsp70 complexes facilitate the identification of context-dependent Hsp70 interactomes.
Results: Our laboratory recently reported the identification of a novel allosteric site located in the nucleotide binding domain of Hsp70 (Chem Biol 2013). It has also reported the discovery of ligands that bind to the allosteric pocket of Hsp70, inhibit its function in cancer cells and result in anti-cancer activity (J Med Chem 2013). Structure-activity relationship studies in this ligand series gave insights on the attachment of specific linkers for the design of Hsp70-related chemical tools. Here we present the design of Hsp70-directed reagents and use biochemical and cell-based methods to validate Hsp70-directed affinity purification probes. We demonstrate that these tools lock Hsp70 in complex with onco-client proteins and effectively isolate Hsp70 complexes for identification through biochemical techniques. Using these tools we provide proof-of-concept analyses that glimpse into the complex roles played by Hsp70 in maintaining a multitude of cell-specific malignancy-driving proteins.
Significance: The knowledge derived from the use of such reagents will be extremely valuable not only to understand tumor-specific roles of Hsp70 and associated mechanisms but also to develop rational strategies for the clinical implementation of these agents to cancer treatment. They may also provide clues on the altered functional proteome in individual tumors, a quest yet elusive by today's proteomics methods.
Citation Format: Anna A. Rodina, Tony Taldone, Yanlong Kang, Pallav Patel, John Koren, Pengrong Yan, Erica DaGama Gomes, Chenghua Yang, Maulik Patel, Liza Shrestha, Stefan Ochiana, Ronnie Maharaj, Alexander Gozman, Marc Cox, Hediye Erdjument-Bromage, Ronald Hendrickson, Leandro Cerchietti, Ari Melnick, Monica Guzman, Gabriela Chiosis. Development of chemical tools to study the endogenous Hsp70 interactome in malignant cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1733. doi:10.1158/1538-7445.AM2015-1733
Collapse
Affiliation(s)
| | - Tony Taldone
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | - Yanlong Kang
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | - Pallav Patel
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | - John Koren
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | - Pengrong Yan
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - Chenghua Yang
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | - Maulik Patel
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | - Liza Shrestha
- 1Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | - Marc Cox
- 2University of Texas, El Paso, TX
| | | | | | | | - Ari Melnick
- 4Weill Cornell Medical College, New York, NY
| | | | | |
Collapse
|
27
|
Herta J, Koren J, Fürbass F, Hartmann M, Kluge T, Baumgartner C, Gruber A. Prospective assessment and validation of rhythmic and periodic pattern detection in NeuroTrend: A new approach for screening continuous EEG in the intensive care unit. Epilepsy Behav 2015; 49:273-9. [PMID: 26004320 DOI: 10.1016/j.yebeh.2015.04.064] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 04/24/2015] [Accepted: 04/28/2015] [Indexed: 11/30/2022]
Abstract
BACKGROUND NeuroTrend is a computational method that analyzes long-term scalp EEGs in the ICU according to ACNS standardized critical care EEG terminology (CCET) including electrographic seizures. At present, it attempts to become a screening aid for continuous EEG (cEEG) recordings in the ICU to facilitate the review process and optimize resources. METHODS A prospective multicenter study was performed in two neurological ICUs including 68 patients who were subjected to video-cEEG. Two reviewers independently annotated the first minute of each hour in the cEEG according to CCET. These segments were also screened for faster patterns with frequencies higher than 4 Hz. The matching annotations (2911 segments) were then used as gold standard condition to test sensitivity and specificity of the rhythmic and periodic pattern detection of NeuroTrend. RESULTS Interrater agreement showed substantial agreement for localization (main term 1) and pattern type (main term 2) of the CCET. The overall detection sensitivity of NeuroTrend was 94% with high detection rates for periodic discharges (PD = 80%) and rhythmic delta activity (RDA = 82%). Overall specificity was moderate (67%) mainly because of false positive detections of RDA in cases of general slowing. In contrast, a detection specificity of 88% for PDs was reached. Localization revealed only a slight agreement between reviewers and NeuroTrend. CONCLUSIONS NeuroTrend might be a suitable screening tool for cEEG in the ICU and has the potential to raise efficiency of long-term EEG monitoring in the ICU. At this stage, pattern localization and differentiation between RDA and general slowing need improvement. This article is part of a Special Issue entitled "Status Epilepticus".
Collapse
Affiliation(s)
- J Herta
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
| | - J Koren
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria
| | - F Fürbass
- AIT Austrian Institute of Technology GmbH, Digital Safety & Security Department, Vienna, Austria
| | - M Hartmann
- AIT Austrian Institute of Technology GmbH, Digital Safety & Security Department, Vienna, Austria
| | - T Kluge
- AIT Austrian Institute of Technology GmbH, Digital Safety & Security Department, Vienna, Austria
| | - C Baumgartner
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria
| | - A Gruber
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
28
|
Koren J, Xu C, Rodina A, Shrestha L, Taldone T, Chiosis G. Abstract 1740: Allosteric Hsp70-family inhibitors as targeted anticancer therapeutics. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-1740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Hsp70, a molecular chaperone responsible, in part, for the folding of nascent peptides following translation, has been implicated as a survival factor and a poor prognostic marker in cancer cells. These pro-cancer mechanisms originate in the ability of Hsp70 to preserve and maintain oncogenic and transformative proteins responsible for the cancer phenotype. Hsp70 is a stress response protein such that expression increases under proteomic/proteotoxic stress events. This increased expression is also evident in cancer cells, an environment under proteomic stress brought on by transformation, and is known to be protective against programmed cell death.
Hypothesis: We predict that by interrupting the chaperoning capacity of Hsp70 through allosteric inhibition, we can destabilize oncogenic proteins dependent on Hsp70 for structure and function. Additionally, as Hsp70 is a survival factor, we believe that a loss of Hsp70 activity will result in cancer specific cell death both in vitro and in vivo.
Approach: Using chemical tools, primarily novel allosteric Hsp70 inhibiting small molecules, we will determine the fate of oncogenic proteins dependent on Hsp70 for stability. We will also examine the cellular response to the disruption of cancer-specific networks which require Hsp70. In vivo tumor models will be used to examine the pharmacokinetics and pharmacodynamics of small molecule Hsp70 inhibitors and to evaluate the therapeutic potential of Hsp70 inhibition.
Significance: The stress response machinery is responsible for the stability of proteins, maintenance of signaling pathways, and evasion from programmed cell death while a cell is under stress; stressors including oncogenic transformation. These pathways maintained by the molecular chaperones have been directly linked to deleterious cancer phenotypes including aggressiveness and the emergence of therapeutic resistances. Targeted therapeutics, and uniquely those targeting the molecular chaperone system, can provide therapeutic options capable of ablating the specific mechanisms involved in proteomic stability and cell survival unique to each tumor cell; effects which can be delivered with minimal effect to normal tissue. This work highlights the potential for therapeutics targeting Hsp70 as anti-cancer agents.
Citation Format: John Koren, Chao Xu, Anna Rodina, Liza Shrestha, Tony Taldone, Gabriela Chiosis. Allosteric Hsp70-family inhibitors as targeted anticancer therapeutics. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1740. doi:10.1158/1538-7445.AM2015-1740
Collapse
Affiliation(s)
- John Koren
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Chao Xu
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Anna Rodina
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Liza Shrestha
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Tony Taldone
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | |
Collapse
|
29
|
Koren J, Herta J, Draschtak S, Pötzl G, Pirker S, Fürbass F, Hartmann M, Kluge T, Baumgartner C. Prediction of rhythmic and periodic EEG patterns and seizures on continuous EEG with early epileptiform discharges. Epilepsy Behav 2015; 49:286-9. [PMID: 25982266 DOI: 10.1016/j.yebeh.2015.04.044] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Accepted: 04/19/2015] [Indexed: 11/19/2022]
Abstract
BACKGROUND Continuous EEG (cEEG) is necessary to document nonconvulsive seizures (NCS), nonconvulsive status epilepticus (NCSE), as well as rhythmic and periodic EEG patterns of 'ictal-interictal uncertainty' (RPPIIU) including periodic discharges, rhythmic delta activity, and spike-and-wave complexes in neurological intensive care patients. However, cEEG is associated with significant recording and analysis efforts. Therefore, predictors from short-term routine EEG with a reasonably high yield are urgently needed in order to select patients for evaluation with cEEG. OBJECTIVE The aim of this study was to assess the prognostic significance of early epileptiform discharges (i.e., within the first 30 min of EEG recording) on the following: (1) incidence of ictal EEG patterns and RPPIIU on subsequent cEEG, (2) occurrence of acute convulsive seizures during the ICU stay, and (3) functional outcome after 6 months of follow-up. METHODS We conducted a separate analysis of the first 30 min and the remaining segments of prospective cEEG recordings according to the ACNS Standardized Critical Care EEG Terminology as well as NCS criteria and review of clinical data of 32 neurological critical care patients. RESULTS In 17 patients with epileptiform discharges within the first 30 min of EEG (group 1), electrographic seizures were observed in 23.5% (n = 4), rhythmic or periodic EEG patterns of 'ictal-interictal uncertainty' in 64.7% (n = 11), and neither electrographic seizures nor RPPIIU in 11.8% (n = 2). In 15 patients with no epileptiform discharges in the first 30 min of EEG (group 2), no electrographic seizures were recorded on subsequent cEEG, RPPIIU were seen in 26.7% (n = 4), and neither electrographic seizures nor RPPIIU in 73.3% (n = 11). The incidence of EEG patterns on cEEG was significantly different between the two groups (p = 0.008). Patients with early epileptiform discharges developed acute seizures more frequently than patients without early epileptiform discharges (p = 0.009). Finally, functional outcome six months after discharge was significantly worse in patients with early epileptiform discharges (p=0.01). CONCLUSIONS Epileptiform discharges within the first 30 min of EEG recording are predictive for the occurrence of ictal EEG patterns and for RPPIIU on subsequent cEEG, for acute convulsive seizures during the ICU stay, and for a worse functional outcome after 6 months of follow-up. This article is part of a Special Issue entitled Status Epilepticus.
Collapse
Affiliation(s)
- J Koren
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria.
| | - J Herta
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria
| | - S Draschtak
- 1st Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria
| | - G Pötzl
- 1st Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria
| | - S Pirker
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria
| | - F Fürbass
- Austrian Institute of Technology GmbH (AIT), Safety & Security Department, Vienna, Austria
| | - M Hartmann
- Austrian Institute of Technology GmbH (AIT), Safety & Security Department, Vienna, Austria
| | - T Kluge
- Austrian Institute of Technology GmbH (AIT), Safety & Security Department, Vienna, Austria
| | - C Baumgartner
- Karl Landsteiner Institute for Clinical Epilepsy Research and Cognitive Neurology, 2nd Neurological Department, General Hospital Hietzing with Neurological Center Rosenhuegel, Vienna, Austria
| |
Collapse
|
30
|
Inda C, Koren J, Boalander A, Panchal P, Gandu S, Chiosis G. P3‐327: Hsp90 inhibition rescues behavioral deficits and reduces tau phosphorylation in ps19 mice model for Alzheimer's disease (AD). Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.1701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
31
|
Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J, Fröhling S, Scholl C, Seufferlein T. HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Res 2014; 74:7125-36. [PMID: 25297628 DOI: 10.1158/0008-5472.can-14-1017] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The kinase PRKD2 (protein kinase D) is a crucial regulator of tumor cell-endothelial cell communication in gastrointestinal tumors and glioblastomas, but its mechanistic contributions to malignant development are not understood. Here, we report that the oncogenic chaperone HSP90 binds to and stabilizes PRKD2 in human cancer cells. Pharmacologic inhibition of HSP90 with structurally divergent small molecules currently in clinical development triggered proteasome-dependent degradation of PRKD2, augmenting apoptosis in human cancer cells of various tissue origins. Conversely, ectopic expression of PRKD2 protected cancer cells from the apoptotic effects of HSP90 abrogation, restoring blood vessel formation in two preclinical models of solid tumors. Mechanistic studies revealed that PRKD2 is essential for hypoxia-induced accumulation of hypoxia-inducible factor-1α (HIF1α) and activation of NF-κB in tumor cells. Notably, ectopic expression of PRKD2 was able to partially restore HIF1α and secreted VEGF-A levels in hypoxic cancer cells treated with HSP90 inhibitors. Taken together, our findings indicate that signals from hypoxia and HSP90 pathways are interconnected and funneled by PRKD2 into the NF-κB/VEGF-A signaling axis to promote tumor angiogenesis and tumor growth.
Collapse
Affiliation(s)
- Ninel Azoitei
- Center for Internal Medicine I, University of Ulm, Ulm, Germany.
| | | | - Cornelia Brunner
- Institute for Physiological Chemistry, University of Ulm, Ulm, Germany
| | - Arefeh Rouhi
- Center for Internal Medicine III, University of Ulm, Ulm, Germany
| | | | | | - Hans Kestler
- Institute for Neuroinformatic, Ulm University, Ulm, Germany
| | - Johan van Lint
- Department of Molecular Cell Biology, Katholieke Universiteit, Leuven, Belgium
| | - Gabriela Chiosis
- Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Institute, New York, New York
| | - John Koren
- Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Institute, New York, New York
| | - Stefan Fröhling
- Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany
| | - Claudia Scholl
- Center for Internal Medicine III, University of Ulm, Ulm, Germany
| | | |
Collapse
|
32
|
Carman A, Kishinevsky S, Koren J, Luo W, Chiosis G. Regulatory chaperone complexes in neurodegenerative diseases: a perspective on therapeutic intervention. Curr Alzheimer Res 2014; 11:59-68. [PMID: 24251390 DOI: 10.2174/1567205010666131119233044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Revised: 11/03/2013] [Accepted: 11/10/2013] [Indexed: 11/22/2022]
Abstract
Protein folding, protein degradation, and protein stability are regulated by the molecular chaperones. Under pathogenic conditions, aberrant proteins can be dysfunctional, unregulated, or pathogenically mutated. These aberrant proteins are triaged by the chaperone network for the maintenance of cellular homeostasis. These species, called chaperone client proteins, include the pathogenic factors of numerous neurodegenerative disorders, including tau in Alzheimer's disease, α-synuclein and LRRK2 in Parkinson's disease, SOD-1, TDP-43 and FUS in amyotrophic lateral sclerosis, and polyQ-expanded proteins such as huntingtin in Huntington's disease. In depth study of two molecular chaperones, Hsp90 and Hsc70, has led to a greater understanding of aberrant client fate and how retarding the chaperone system can promote clearance of these pathogenic clients. Here we discuss how chaperone interactions and small molecule inhibitors can regulate the burden of aberrant client signaling in these neurological disorders.
Collapse
Affiliation(s)
| | | | | | | | - Gabriela Chiosis
- Molecular Pharmacology & Chemistry, Sloan-Kettering Institute, Associate Attending, Breast Cancer Service, Department of Medicine, Memorial Hospital, Memorial Sloan- Kettering Cancer Center, ZRB2103, Associate Professor, Weill Graduate School of Medical Sciences, New York, USA.
| |
Collapse
|
33
|
Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, DaGama Gomes EM, Yang C, Patel MR, Shrestha L, Ochiana SO, Santarossa C, Maharaj R, Gozman A, Cox MB, Erdjument-Bromage H, Hendrickson RC, Cerchietti L, Melnick A, Guzman ML, Chiosis G. Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. ACS Chem Biol 2014; 9:1698-705. [PMID: 24934503 PMCID: PMC4134716 DOI: 10.1021/cb500256u] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2014] [Accepted: 06/11/2014] [Indexed: 01/08/2023]
Abstract
Heat shock protein 70 (Hsp70) is a family of proteins with key roles in regulating malignancy. Cancer cells rely on Hsp70 to inhibit apoptosis, regulate senescence and autophagy, and maintain the stability of numerous onco-proteins. Despite these important biological functions in cancer, robust chemical tools that enable the analysis of the Hsp70-regulated proteome in a tumor-by-tumor manner are yet unavailable. Here we take advantage of a recently reported Hsp70 ligand to design and develop an affinity purification chemical toolset for potential use in the investigation of the endogenous Hsp70-interacting proteome in cancer. We demonstrate that these tools lock Hsp70 in complex with onco-client proteins and effectively isolate Hsp70 complexes for identification through biochemical techniques. Using these tools we provide proof-of-concept analyses that glimpse into the complex roles played by Hsp70 in maintaining a multitude of cell-specific malignancy-driving proteins.
Collapse
Affiliation(s)
- Anna Rodina
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Tony Taldone
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Yanlong Kang
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Pallav D. Patel
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - John Koren
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Pengrong Yan
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Erica M. DaGama Gomes
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Chenghua Yang
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Maulik R. Patel
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Liza Shrestha
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Stefan O. Ochiana
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Cristina Santarossa
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Ronnie Maharaj
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Alexander Gozman
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Marc B. Cox
- Department of Biological Sciences, University
of Texas, El Paso, Texas 79968, United
States
| | - Hediye Erdjument-Bromage
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Ronald C. Hendrickson
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| | - Leandro Cerchietti
- Department of Medicine, Division of Hematology and Medical
Oncology, and Department of Pharmacology, Weill Cornell Medical College, New York, New York 10065, United States
| | - Ari Melnick
- Department of Medicine, Division of Hematology and Medical
Oncology, and Department of Pharmacology, Weill Cornell Medical College, New York, New York 10065, United States
| | - Monica L. Guzman
- Department of Medicine, Division of Hematology and Medical
Oncology, and Department of Pharmacology, Weill Cornell Medical College, New York, New York 10065, United States
| | - Gabriela Chiosis
- Program in Molecular Pharmacology
and Chemistry and Department of Medicine and Program in Molecular Biology, Proteomics
Core, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
| |
Collapse
|
34
|
Jhaveri K, Ochiana SO, Dunphy MPS, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J, Modi S, Chiosis G. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs 2014; 23:611-28. [PMID: 24669860 PMCID: PMC4161020 DOI: 10.1517/13543784.2014.902442] [Citation(s) in RCA: 125] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
INTRODUCTION Heat shock protein 90 (HSP90) serves as a critical facilitator for oncogene addiction. There has been augmenting enthusiasm in pursuing HSP90 as an anticancer strategy. In fact, since the initial serendipitous discovery that geldanamycin (GM) inhibits HSP90, the field has rapidly moved from proof-of-concept clinical studies with GM derivatives to novel second-generation inhibitors. AREAS COVERED The authors highlight the current status of the second-generation HSP90 inhibitors in clinical development. Herein, the authors note the lessons learned from the completed clinical trials of first- and second-generation inhibitors and describe various assays attempting to serve for a more rational implementation of these agents to cancer treatment. Finally, the authors discuss the future perspectives for this promising class of agents. EXPERT OPINION The knowledge gained thus far provides perhaps only a glimpse at the potential of HSP90 for which there is still much work to be done. Lessons from the clinical trials suggest that HSP90 therapy would advance at a faster pace if patient selection and tumor pharmacokinetics of these drugs were better understood and applied to their clinical development. It is also evident that combining HSP90 inhibitors with other potent anticancer therapies holds great promise not only due to synergistic antitumor activity but also due to the potential of prolonging or preventing the development of drug resistance.
Collapse
Affiliation(s)
- Komal Jhaveri
- New York University Cancer Institute, NYU Clinical Cancer Center, Division of Hematology/Medical Oncology, NY, USA
| | - Stefan O Ochiana
- Sloan-Kettering Institute, Molecular Pharmacology and Chemistry Program, NY, USA
| | - Mark PS Dunphy
- Memorial Sloan-Kettering Cancer Center, Department of Radiology, NY, USA
| | - John F Gerecitano
- Memorial Sloan-Kettering Cancer Center, Lymphoma Medicine Service, NY, USA
| | - Adriana D Corben
- Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, NY, USA
| | - Radu I Peter
- Technical University of Cluj-Napoca, Department of Mathematics, Cluj-Napoca, Romania
| | - Yelena Y Janjigian
- Memorial Sloan-Kettering Cancer Center, Gastrointestinal Oncology Service, NY, USA
| | - Erica M Gomes-DaGama
- Sloan-Kettering Institute, Molecular Pharmacology and Chemistry Program, NY, USA
| | - John Koren
- Sloan-Kettering Institute, Molecular Pharmacology and Chemistry Program, NY, USA
| | - Shanu Modi
- Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, NY, USA
| | - Gabriela Chiosis
- Sloan-Kettering Institute, Molecular Pharmacology and Chemistry Program, NY, USA
- Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, NY, USA
- Molecular Pharmacology & Chemistry, Sloan-Kettering Institute, Department of Medicine, Breast Cancer Service, Memorial Hospital, Memorial Sloan-Kettering Cancer Center, and Weill Graduate School of Medical Sciences, NY, USA
| |
Collapse
|
35
|
Fürbass F, Baumgartner C, Koren J, Hartmann M, Weinkopf M, Halford J, Schnabel K, Herta J, Gruber A, Kluge T. New approach in quantitative EEG monitoring of critical care patients: Neurological trending based on the ACNS terminology. KLIN NEUROPHYSIOL 2014. [DOI: 10.1055/s-0034-1371271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
O'Leary JC, Zhang B, Koren J, Blair L, Dickey CA. The role of FKBP5 in mood disorders: action of FKBP5 on steroid hormone receptors leads to questions about its evolutionary importance. CNS Neurol Disord Drug Targets 2013; 12:1157-1162. [PMID: 24040820 PMCID: PMC4236834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 08/10/2013] [Accepted: 08/25/2013] [Indexed: 06/02/2023]
Abstract
Research on the FKBP5 gene and FKBP51 protein has more than doubled since the discovery that polymorphisms in this gene could alter treatment outcomes and depressive behavior in humans. This coincided with other data suggesting that the stress hormone axis contributes to the development of numerous mental illnesses. As a result, FKBP51 now lies at the heart of the research of many stress related psychiatric disorders, which has led to advances in the understanding of this protein and its role in humans and in animal models. Specifically, FKBP5-/- mice and a naturally existing overexpression of FKBP5 in 3 genera of new world monkeys have helped understand the effects of FKBP5 in vivo. This review will highlight these finding as well as discuss the current evolutionary need for the FKBP5 gene.
Collapse
Affiliation(s)
| | | | | | | | - Chad A Dickey
- Deaprtemtn of University of South Florida, 4001 E. Fletcher Ave MDC 36, FL 33613, USA.
| |
Collapse
|
37
|
Abisambra J, Jinwal UK, Miyata Y, Rogers J, Blair L, Li X, Seguin SP, Wang L, Jin Y, Bacon J, Brady S, Cockman M, Guidi C, Zhang J, Koren J, Young ZT, Atkins CA, Zhang B, Lawson LY, Weeber EJ, Brodsky JL, Gestwicki JE, Dickey CA. Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry 2013; 74:367-74. [PMID: 23607970 PMCID: PMC3740016 DOI: 10.1016/j.biopsych.2013.02.027] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Revised: 02/05/2013] [Accepted: 02/22/2013] [Indexed: 02/03/2023]
Abstract
BACKGROUND The microtubule-associated protein tau accumulates in neurodegenerative diseases known as tauopathies, the most common being Alzheimer's disease. One way to treat these disorders may be to reduce abnormal tau levels through chaperone manipulation, thus subverting synaptic plasticity defects caused by tau's toxic accretion. METHODS Tauopathy models were used to study the impact of YM-01 on tau. YM-01 is an allosteric promoter of triage functions of the most abundant variant of the heat shock protein 70 (Hsp70) family in the brain, heat shock cognate 70 protein (Hsc70). The mechanisms by which YM-01 modified Hsc70 activity and tau stability were evaluated with biochemical methods, cell cultures, and primary neuronal cultures from tau transgenic mice. YM-01 was also administered to acute brain slices of tau mice; changes in tau stability and electrophysiological correlates of learning and memory were measured. RESULTS Tau levels were rapidly and potently reduced in vitro and ex vivo upon treatment with nanomolar concentrations of YM-01. Consistent with Hsc70 having a key role in this process, overexpression of heat shock protein 40 (DNAJB2), an Hsp70 co-chaperone, suppressed YM-01 activity. In contrast to its effects in pathogenic tauopathy models, YM-01 had little activity in ex vivo brain slices from normal, wild-type mice unless microtubules were disrupted, suggesting that Hsc70 acts preferentially on abnormal pools of free tau. Finally, treatment with YM-01 increased long-term potentiation in tau transgenic brain slices. CONCLUSIONS Therapeutics that exploit the ability of chaperones to selectively target abnormal tau can rapidly and potently rescue the synaptic dysfunction that occurs in Alzheimer's disease and other tauopathies.
Collapse
Affiliation(s)
- Jose Abisambra
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Umesh K. Jinwal
- Department of Pharmaceutical Sciences, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Yoshinari Miyata
- Life Sciences Institute and Departments of Pathology and Biological Chemistry, University of Michigan; Ann Arbor, MI, 48109, USA
| | - Justin Rogers
- Department of Molecular Pharmacology and Physiology, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Laura Blair
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Xiaokai Li
- Life Sciences Institute and Departments of Pathology and Biological Chemistry, University of Michigan; Ann Arbor, MI, 48109, USA
| | - Sandlin P. Seguin
- Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260
| | - Li Wang
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Ying Jin
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Justin Bacon
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Sarah Brady
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Matthew Cockman
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Chantal Guidi
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Juan Zhang
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - John Koren
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Zapporah T. Young
- Life Sciences Institute and Departments of Pathology and Biological Chemistry, University of Michigan; Ann Arbor, MI, 48109, USA
| | - Christopher A. Atkins
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Bo Zhang
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Lisa Y. Lawson
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Edwin J. Weeber
- Department of Molecular Pharmacology and Physiology, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| | - Jeffrey L. Brodsky
- Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260
| | - Jason E. Gestwicki
- Life Sciences Institute and Departments of Pathology and Biological Chemistry, University of Michigan; Ann Arbor, MI, 48109, USA
| | - Chad A. Dickey
- Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida; Tampa, FL, 33613, USA
| |
Collapse
|
38
|
Dubrava J, Koren J, Pospisilova V. Mediastinal foregut duplication cyst of enteric type containing a persistent thymus, imitating a pericardial cyst. ACTA ACUST UNITED AC 2013; 114:480-3. [PMID: 23944625 DOI: 10.4149/bll_2013_100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
UNLABELLED Mediastinal foregut duplication cysts are rare congenital masses caused by developmental disorders of the anterior part of the embryonic primitive gut. In adults they can be discovered as an incidental finding on chest radiograph. They can mimic other intrathoracic pathologies as it was initially the case in our patient. A 51-year-old woman was incidentally found to have homogenous mass at the right cardiophrenic angle on the chest radiograph. Based on that finding and echocardiography a pericardial cyst was suspected. Computed tomography demonstrated a simple anterior mediastinal cyst. Because of the growth with a mild progression of the compression of the right atrium, the cyst was resected. Histology and immunohistochemistry revealed the mass to be a mediastinal foregut duplicatory cyst of enteric type containing persistent thymus. To our knowledge, this is the first report in which a mediastinal foregut cyst contained both enteric mucosa and ectopic persistent thymus (Fig. 9, Ref. 13). KEYWORDS foregut cyst, mediastinal cyst, thymus, enteric cyst, pericardial cyst.
Collapse
Affiliation(s)
- J Dubrava
- Department of Noninvasive Cardiology, St. Cyril and Method Hospital, Bratislava, Slovakia
| | | | | |
Collapse
|
39
|
Koren J, Inda MC, Riolo M, Uddin M, Alonso‐Sabadell R, Chiosis G. P1–402: Blood‐brain‐barrier–permeable Hsp90 inhibitor reduces soluble tau burden in a mouse model of Alzheimer's disease. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- John Koren
- Memorial Sloan‐Kettering Cancer Center New York New York United States
| | | | - Matthew Riolo
- Memorial Sloan‐Kettering New York New York United States
| | - Mohammad Uddin
- Memorial Sloan‐Kettering New York New York United States
| | | | | |
Collapse
|
40
|
Abstract
Imbalanced protein load within cells is a critical aspect for most diseases of aging. In particular, the accumulation of proteins into neurotoxic aggregates is a common thread for a host of neurodegenerative diseases. Recent work demonstrates that age-related changes to the cellular chaperone repertoire contributes to abnormal buildup of the microtubule-associated protein tau that accumulates in a group of diseases termed tauopathies, the most common being Alzheimer's disease (AD). The Hsp90 co-chaperone repertoire has diverse effects on tau stability; some co-chaperones stabilize tau while others facilitate its clearance. We propose that each of these proteins may be novel therapeutic targets. While targeting Hsp90 directly may be deleterious at the organismal level, perhaps targeting individual co-chaperone activities will be more tolerable.
Collapse
Affiliation(s)
- Umesh K Jinwal
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, Tampa, Florida 33613
| | | | | |
Collapse
|
41
|
Abstract
Maintenance of cellular homeostasis is regulated by the molecular chaperones. Under pathogenic conditions, aberrant proteins are triaged by the chaperone network. These aberrant proteins, known as "clients," have major roles in the pathogenesis of numerous neurological disorders, including tau in Alzheimer's disease, α-synuclein and LRRK2 in Parkinson's disease, SOD-1, TDP-43 and FUS in amyotrophic lateral sclerosis, and polyQ-expanded proteins such as huntingtin in Huntington's disease. Recent work has demonstrated that the use of chemical compounds which inhibit the activity of molecular chaperones subsequently alter the fate of aberrant clients. Inhibition of Hsp90 and Hsc70, two major molecular chaperones, has led to a greater understanding of how chaperone triage decisions are made and how perturbing the chaperone system can promote clearance of these pathogenic clients. Described here are major pathways and components of several prominent neurological disorders. Also discussed is how treatment with chaperone inhibitors, predominately Hsp90 inhibitors which are selective for a diseased state, can relieve the burden of aberrant client signaling in these neurological disorders.
Collapse
Affiliation(s)
- Aaron Carman
- Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA
| | - Sarah Kishinevsky
- Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA
| | - John Koren
- Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA
| | - Wenjie Lou
- Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY, USA
| | - Gabriela Chiosis
- Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA
| |
Collapse
|
42
|
Suntharalingam A, Abisambra JF, O'Leary JC, Koren J, Zhang B, Joe MK, Blair LJ, Hill SE, Jinwal UK, Cockman M, Duerfeldt AS, Tomarev S, Blagg BSJ, Lieberman RL, Dickey CA. Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism. J Biol Chem 2012; 287:40661-9. [PMID: 23035116 DOI: 10.1074/jbc.m112.384800] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Mutant myocilin accumulates in the endoplasmic reticulum for unknown reasons. RESULTS Glucose-regulated protein (Grp) 94 depletion reduces mutant myocilin by engaging autophagy. CONCLUSION Grp94 triages mutant myocilin through ER-associated degradation, subverting autophagy. SIGNIFICANCE Treating glaucoma could be possible by inhibiting Grp94 and reducing its novel client, mutant myocilin. Clearance of misfolded proteins in the endoplasmic reticulum (ER) is traditionally handled by ER-associated degradation (ERAD), a process that requires retro-translocation and ubiquitination mediated by a luminal chaperone network. Here we investigated whether the secreted, glaucoma-associated protein myocilin was processed by this pathway. Myocilin is typically transported through the ER/Golgi network, but inherited mutations in myocilin lead to its misfolding and aggregation within trabecular meshwork cells, and ultimately, ER stress-induced cell death. Using targeted knockdown strategies, we determined that glucose-regulated protein 94 (Grp94), the ER equivalent of heat shock protein 90 (Hsp90), specifically recognizes mutant myocilin, triaging it through ERAD. The addition of mutant myocilin to the short list of Grp94 clients strengthens the hypothesis that β-strand secondary structure drives client association with Grp94. Interestingly, the ERAD pathway is incapable of efficiently handling the removal of mutant myocilin, but when Grp94 is depleted, degradation of mutant myocilin is shunted away from ERAD toward a more robust clearance pathway for aggregation-prone proteins, the autophagy system. Thus ERAD inefficiency for distinct aggregation-prone proteins can be subverted by manipulating ER chaperones, leading to more effective clearance by the autophagic/lysosomal pathway. General Hsp90 inhibitors and a selective Grp94 inhibitor also facilitate clearance of mutant myocilin, suggesting that therapeutic approaches aimed at inhibiting Grp94 could be beneficial for patients suffering from some cases of myocilin glaucoma.
Collapse
Affiliation(s)
- Amirthaa Suntharalingam
- Department of Molecular Medicine and Byrd Alzheimer's Research Institute, University of South Florida, Tampa, FL 33613, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abisambra JF, Jinwal UK, Jones JR, Blair LJ, Koren J, Dickey CA. Exploiting the diversity of the heat-shock protein family for primary and secondary tauopathy therapeutics. Curr Neuropharmacol 2012; 9:623-31. [PMID: 22654720 PMCID: PMC3263456 DOI: 10.2174/157015911798376226] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2010] [Revised: 11/01/2010] [Accepted: 12/06/2010] [Indexed: 12/17/2022] Open
Abstract
The heat shock protein (Hsp) family is an evolutionarily conserved system that is charged with preventing unfolded or misfolded proteins in the cell from aggregating. In Alzheimer’s disease, extracellular accumulation of the amyloid β peptide (Aβ) and intracellular aggregation of the microtubule associated protein tau may result from mechanisms involving chaperone proteins like the Hsps. Due to the ability of Hsps to regulate aberrantly accumulating proteins like Aβ and tau, therapeutic strategies are emerging that target this family of chaperones to modulate their pathobiology. This article focuses on the use of Hsp-based therapeutics for treating primary and secondary tauopathies like Alzheimer’s disease. It will particularly focus on the pharmacological targeting of the Hsp70/90 system and the value of manipulating Hsp27 for treating Alzheimer’s disease.
Collapse
Affiliation(s)
- Jose F Abisambra
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, Tampa, FL 33613, USA
| | | | | | | | | | | |
Collapse
|
44
|
Koren J, Miyata Y, Kiray J, O'Leary JC, Nguyen L, Guo J, Blair LJ, Li X, Jinwal UK, Cheng JQ, Gestwicki JE, Dickey CA. Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance. PLoS One 2012; 7:e35566. [PMID: 22563386 PMCID: PMC3338522 DOI: 10.1371/journal.pone.0035566] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2012] [Accepted: 03/17/2012] [Indexed: 11/18/2022] Open
Abstract
MKT-077, a rhodacyanine dye, was shown to produce cancer specific cell death. However, complications prevented the use of this compound beyond clinical trials. Here we describe YM-1, a derivative of MKT-077. We found that YM-1 was more cytotoxic and localized differently than MKT-077. YM-1 demonstrated this cytotoxicity across multiple cancer cell lines. This toxicity was limited to cancer cell lines; immortalized cell models were unaffected. Brief applications of YM-1 were found to be non-toxic. Brief treatment with YM-1 restored tamoxifen sensitivity to a refractory tamoxifen-resistant MCF7 cell model. This effect is potentially due to altered estrogen receptor alpha phosphorylation, an outcome precipitated by selective reductions in Akt levels (Akt/PKB). Thus, modifications to the rhodocyanine scaffold could potentially be made to improve efficacy and pharmacokinetic properties. Moreover, the impact on tamoxifen sensitivity could be a new utility for this compound family.
Collapse
Affiliation(s)
- John Koren
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Yoshinari Miyata
- Departments of Pathology and Biological Chemistry, Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Janine Kiray
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - John C. O'Leary
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Lana Nguyen
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Jianping Guo
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
| | - Laura J. Blair
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, College of Medicine, University of South Florida, Tampa, Florida, United States of America
| | - Xiokai Li
- Departments of Pathology and Biological Chemistry, Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Umesh K. Jinwal
- College of Pharmacy, University of South Florida, Tampa, Florida, United States of America
| | - Jin Q. Cheng
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
| | - Jason E. Gestwicki
- Departments of Pathology and Biological Chemistry, Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, United States of America
| | - Chad A. Dickey
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, College of Medicine, University of South Florida, Tampa, Florida, United States of America
- * E-mail:
| |
Collapse
|
45
|
O'Leary JC, Koren J, Dickey CA. Neuronal life span versus health span: principles of natural selection at work in the degenerating brain. J Mol Neurosci 2011; 45:467-72. [PMID: 21559875 PMCID: PMC4235992 DOI: 10.1007/s12031-011-9540-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Accepted: 04/28/2011] [Indexed: 01/26/2023]
Abstract
Impaired nutrient delivery to the brain due to decreased blood flow contributes to cognitive decline and dementia in Alzheimer's disease (AD). Considering this, many studies have suggested that neuroprotective agents like those used in stroke could prevent AD onset or progression by promoting cell survival. However, research in the past decade suggests that the culprit behind the cognitive loss in AD models is actually the soluble tau accumulating inside of surviving neurons. In fact, tau reductions improve cognition in mouse models of AD, even those that only deposit amyloid plaques. There is emerging evidence that neuroprotection alone in these AD models may be insufficient to restore neuron function and cognition. Only when soluble tau is reduced on a neuroprotective background could memory be rescued. Thus, once a neuron begins to accumulate tau, it may survive in a malfunctioning capacity, leading to impaired electrical signaling and memory formation in the brain. These data imply that multiple drugs may be necessary to ameliorate the different disease components. In fact, strategies to preserve neurons without affecting the soluble protein burden within neurons may accelerate the disease course.
Collapse
Affiliation(s)
- John C O'Leary
- USF Health Byrd Alzheimer's Institute, Tampa, FL 33613, USA
| | | | | |
Collapse
|
46
|
Voss K, Koren J, Dickey CA. The earliest tau dysfunction in Alzheimer's disease? Tau phosphorylated at s422 as a toxic seed. Am J Pathol 2011; 179:2148-51. [PMID: 21964186 DOI: 10.1016/j.ajpath.2011.08.020] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2011] [Accepted: 08/22/2011] [Indexed: 11/17/2022]
Affiliation(s)
- Kellen Voss
- USF Health Byrd Alzheimer's Institute, Department of Molecular Medicine, University of South Florida, Tampa, Florida, USA
| | | | | |
Collapse
|
47
|
Abisambra J, Cannon A, O'Leary J, Brady S, Espinosa A, Jinwal U, Koren J, Blair L, Lewis J, Dickey C. O4‐04‐08: Neuronal tau‐specific stress induction of molecular chaperones: The failure of a coping mechanism. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.1996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
| | | | - John O'Leary
- Univerity of South Florida Health Byrd InstituteTampaFlo.United States
| | - Sarah Brady
- Univerity of South Florida Health Byrd InstituteTampaFlo.United States
| | - Adriana Espinosa
- Univerity of South Florida Health Byrd InstituteTampaFlo.United States
| | - Umesh Jinwal
- Univerity of South Florida Health Byrd InstituteTampaFlo.United States
| | - John Koren
- Univerity of South Florida Health Byrd InstituteTampaFlo.United States
| | - Laura Blair
- Univerity of South Florida Health Byrd InstituteTampaFlo.United States
| | - Jada Lewis
- University of FloridaGainesvilleFlo.United States
| | - Chad Dickey
- Univerity of South Florida Health Byrd InstituteTampaFlo.United States
| |
Collapse
|
48
|
Jinwal U, Abisambra J, Koren J, O'Leary J, Blair L, Hill S, Trotter J, Mushcol M, Weeber E, Gestwicki J, Dickey C. P3‐124: Exploiting the diversity of the chaperone repertoire to treat tauopathies. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.1565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Umesh Jinwal
- University of South FloridaTampaFloridaUnited States
| | | | - John Koren
- University of South FloridaTampaFloridaUnited States
| | - John O'Leary
- University of South FloridaTampaFloridaUnited States
| | - Laura Blair
- University of South FloridaTampaFloridaUnited States
| | - Shannon Hill
- University of South FloridaTampaFloridaUnited States
| | | | | | - Edwin Weeber
- University of South FloridaTampaFloridaUnited States
| | | | - Chad Dickey
- University of South FloridaTampaFloridaUnited States
| |
Collapse
|
49
|
Koren J, Jinwal UK, Davey Z, Kiray J, Arulselvam K, Dickey CA. Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies. Mol Neurobiol 2011; 44:65-70. [PMID: 21523562 DOI: 10.1007/s12035-011-8182-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2011] [Accepted: 04/12/2011] [Indexed: 01/21/2023]
Abstract
The Hsp90-associated cis-trans peptidyl-prolyl isomerase--FK506 binding protein 51 (FKBP51)--was recently found to co-localize with the microtubule (MT)-associated protein tau in neurons and physically interact with tau in brain tissues from humans who died from Alzheimer's disease (AD). Tau pathologically aggregates in neurons, a process that is closely linked with cognitive deficits in AD. Tau typically functions to stabilize and bundle MTs. Cellular events like calcium influx destabilize MTs, disengaging tau. This excess tau should be degraded, but sometimes it is stabilized and forms higher-order aggregates, a pathogenic hallmark of tauopathies. FKBP51 was also found to increase in forebrain neurons with age, further supporting a novel role for FKBP51 in tau processing. This, combined with compelling evidence that the prolyl isomerase Pin1 regulates tau stability and phosphorylation dynamics, suggests an emerging role for isomerization in tau pathogenesis.
Collapse
Affiliation(s)
- John Koren
- Department of Molecular Medicine, USF Health Byrd Alzheimer's Institute, Tampa, FL 33613, USA
| | | | | | | | | | | |
Collapse
|
50
|
Koren J, Miyata Y, Kiray J, Guo J, Gestwicki J, Cheng JQ, Dickey C. Abstract 2094: Hsp70 inhibitors overcome tamoxifen resistance, in cell culture model. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-2094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
A prevalent problem in the use of chemotherapies for the treatment of human cancers is the potential for the development of resistance. While the exact nature of the mechanisms involved in resistance development vary based on cancer type as well as the nature of the therapeutics; some oncogenic factors have been established to have roles in the desensitization to common treatments. Previous data from our lab demonstrated Hsp70 inhibitors can reduce Akt levels. a major proliferation and survival factor also linked to estrogen receptor therapeutic based resistance. We have, Uusing these Hsp70 ATPase-inhibiting compounds and ain a cell culture model of tamoxifen resistant breast cancer, we have identified compounds which can re-sensitize resistant cells. These compounds inhibit cytosolic and mitochondrial members of the 70-kDA heat-shock protein family. These compounds also reduce Akt levels, a major proliferation and survival factor also linked to estrogen receptor therapeutic based resistance, as well as Thus, in addition to reducing Akt levels and possibly other oncogenic chaperone clients, these drugs may also interrupt mitochondrial function leading to reduced viability in the presence of tamoxifen. With these mechanisms in mind, we now have data that Ttamoxifen resistant MCF7 cells regained sensitivity to tamoxifen after brief treatments with Hsp70-family inhibitors. The resistant cells were grown in media containing tamoxifen. This media was replaced with media containing an Hsp70 inhibitor compound for four hours. After the four hours, the Hsp70 inhibitor media was removed and tamoxifen-containing media was reapplied to the cells. Multiple viability and cytotoxicity assays confirm the drop in viability and increased cytotoxicity following these treatments. These studies demonstrate that Hsp70 family members are potentially valuable targets for new cancer therapeutics.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2094. doi:10.1158/1538-7445.AM2011-2094
Collapse
Affiliation(s)
| | | | | | - Jianping Guo
- 3H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | | | - Jin Q. Cheng
- 3H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | | |
Collapse
|